Aqua Bio Technology — Share Issue/Capital Change 2026

Mar 19, 2026

Aqua Bio Technology ASA: Last day of subscription period in the Subsequent Offering

Aqua Bio Technology ASA: Last day of subscription period in the Subsequent Offering

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR

INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED

STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR

DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER

OF ANY OF THE SECURITIES DESCRIBED HEREIN

Reference is made to the stock exchange announcements by Aqua Bio Technology

ASA ("ABTEC" or the "Company") on 11 March 2026 regarding the terms of a

subsequent offering of up to 800,000 new shares (the "Offer Shares") in the

Company (the "Subsequent Offering") and on 12 March 2026 regarding the start

of the subscription period in the Subsequent Offering. Each Offer Share is

offered at a subscription price of NOK 5.00.

The subscription period for the Subsequent Offering (the "Subscription

Period") will expire today, 19 March 2026 at 16:30 hours (CET). Subscription

rights that are not used to subscribe for Offer Shares before the expiry of

the Subscription Period will have no value and will lapse without compensation

to the holder. Over-subscription will be permitted.

Correctly completed subscription forms must be received by DNB Carnegie Issuer

Services (the "Settlement Agent") prior to the expiry of the Subscription

Period, or in the case of online subscriptions, be registered prior to the

expiry of the Subscription Period.

Subscriptions may be made through the VPS' online subscription system, or by

correctly completing and signing the subscription form included in the

invitation letter. Eligible shareholders who are residents of Norway with a

Norwegian national identity number, and Norwegian private/public limited

companies (AS/ASA), may be made electronically through an online subscription

system through a link available on the Company's website:

https://aquabiotechnology.com/press-releases/.

For further information on the Subsequent Offering, please refer to the

Company's stock exchange notice dated 12 March 2026, and the invitation letter

attached thereto.

IMPORTANT INFORMATION

This announcement is not an offer to sell or a solicitation of offers to

purchase or subscribe for shares. Copies of this announcement may not be sent

to jurisdictions, or distributed in or sent from jurisdictions, in which this

is barred or prohibited by law. The information contained herein shall not

constitute an offer to sell or the solicitation of an offer to buy, in any

jurisdiction in which such offer or solicitation would be unlawful absent

registration, or an exemption from registration or qualification under the

securities laws of any jurisdiction.

This document is not for publication or distribution in, directly or

indirectly, Australia, Canada, Japan, Hong Kong or the United States or any

other jurisdiction in which such release, publication or distribution would be

unlawful, and it does not constitute an offer or invitation to subscribe for

or purchase any securities in such countries or in any other jurisdiction. In

particular, the document and the information contained herein should not be

distributed or otherwise transmitted into the United States or to publications

with a general circulation in the United States of America.

This announcement is not an offer for sale of securities in the United States.

Securities may not be offered or sold in the United States absent registration

with the United States Securities and Exchange Commission or an exemption from

registration under the U.S. Securities Act of 1933, as amended (the

"Securities Act"). The Company does not intend to register any part of the

offering in the United States or to conduct a public offering in the United

States of the shares to which this document relates. This announcement is for

information purposes only and is not to be relied upon in substitution for the

exercise of independent judgment. It is not intended as investment advice and

under no circumstances is it to be used or considered as an offer to sell, or

a solicitation of an offer to buy any securities or a recommendation to buy or

sell any securities of the Company.

This announcement and any materials distributed in connection with this

announcement may contain certain forward-looking statements. By their nature,

forward-looking statements involve risk and uncertainty because they reflect

current expectations and assumptions as to future events and circumstances

that may not prove accurate. A number of material factors could cause actual

results and developments to differ materially from those expressed or implied

by these forward-looking statements.

The Company expressly disclaims any obligation or undertaking to update,

review or revise any statement contained in this announcement whether as a

result of new information, future developments or otherwise.

Contacts

Kristian Flaten

CEO & CFO

Aqua Bio Technology ASA

Phone: +47 9509 2322

Email: kf@aquabiotech.no

About Us

Aqua Bio Technology ASA (ABTEC) is a technology and distribution group in

skincare and nonfood. The group has distribution towards B2C and B2B, and

offers freight, customs, and logistics services. The group also develops

sustainable biotechnology for use in skincare products. Aqua Bio Technology is

listed on Euronext Expand Oslo.

This notice is published by Kristian Flaten on the listed date and time.

This information has been submitted pursuant to the Securities Trading Act §

5-12 and MAR. The information was submitted for publication, through the

agency of the contact persons set out above, at 2026-03-19 08:00 CET.